KPC Pharmaceuticals Inc banner

KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 11.08 CNY -0.27% Market Closed
Market Cap: ¥8.4B

EV/EBITDA

24.2
Current
28%
More Expensive
vs 3-y average of 18.9

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
24.2
=
Enterprise Value
¥7.8B
/
EBITDA
¥320.2m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
24.2
=
Enterprise Value
¥7.8B
/
EBITDA
¥320.2m

Valuation Scenarios

KPC Pharmaceuticals Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (18.9), the stock would be worth ¥8.67 (22% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-28%
Maximum Upside
+19%
Average Downside
8%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 24.2 ¥11.08
0%
3-Year Average 18.9 ¥8.67
-22%
5-Year Average 17.5 ¥8
-28%
Industry Average 23.9 ¥10.94
-1%
Country Average 28.8 ¥13.19
+19%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥7.8B
/
Jan 2026
¥320.2m
=
24.2
Current
¥7.8B
/
Dec 2026
¥697.5m
=
11.2
Forward
¥7.8B
/
Dec 2027
¥817.5m
=
9.6
Forward
¥7.8B
/
Dec 2028
¥539.7m
=
14.5
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
KPC Pharmaceuticals Inc
SSE:600422
8.4B CNY 24.2 24
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 27.4 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 16.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.9 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 15.6 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 12.1 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 9.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8.4 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 7.6 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 7.2 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
KPC Pharmaceuticals Inc
SSE:600422
Average EV/EBITDA: 47.9
24.2
19%
1.3
US
Eli Lilly and Co
NYSE:LLY
27.4
21%
1.3
US
Johnson & Johnson
NYSE:JNJ
16.7
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
15.6
12%
1.3
CH
Novartis AG
SIX:NOVN
12.1
5%
2.4
US
Merck & Co Inc
NYSE:MRK
9.5
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.4
2%
4.2
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-9%
N/A
P/E Multiple
Earnings Growth PEG
CN
KPC Pharmaceuticals Inc
SSE:600422
Average P/E: 22.1
24
10%
2.4
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in China
Percentile
45th
Based on 5 409 companies
45th percentile
24.2
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

KPC Pharmaceuticals Inc
Glance View

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
10.17 CNY
Overvaluation 8%
Intrinsic Value
Price ¥11.08
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett